Detection of three types of hepatitis C virus in blood donors: investigation of type‐specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities

  title={Detection of three types of hepatitis C virus in blood donors: investigation of type‐specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities},
  author={Fiona Mcomish and Sau-wan Chan and Brian C. Dow and Jack Gillon and W. D. Frame and R. J. Crawford and P. L. Yap and E. A. C. Follett and Peter Simmonds},
The serologic reactivity and epidemiology associated with different hepatitis C virus (HCV) variants were investigated in a cohort of 113 anti‐HCV‐positive donors. In Scotland, HCV type 1 accounted for one‐ half of all infections; 40 percent of subjects were infected with HCV type 3, and the remainder were infected with type 2. Reactivity with the NS‐4‐encoded antigens in the first‐generation anti‐c100 assay was absent in 68 percent of donors infected with types 2 and 3, as compared with 10… 

Hepatitis C virus (HCV) genotype analysis in apparently healthy anti‐ HCV‐positive Parisian blood donors

Among the sampled population, an HCV prevalence rate of 0.26 percent was found, with the five most common European genotypes causing the infections, and links with age, sex, and ethnic origin emerged.

Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease.

The heterogeneous pattern ofHCV genotype distribution in this cohort of patients and the observed relationship between the severity of the related liver disease and specific HCV genotypes may have important implications with respect to the natural history and treatment of HCV-related chronic liver disease in infected hemophiliacs worldwide.

Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second‐generation recombinant immunoblot assay

Based on relatively high prevalence of chronic hepatitis in apparently healthy subjects with stable indeterminate RIBA‐2 pattern and HCV RNA positivity should be considered for liver biopsy independently of ALT profile.

Hepatitis C virus (HCV) core serotypes in chronic HCV infection

HCV core serologic typing is a simple, inexpensive, and highly reproducible assay that can be applied to more than 50% of viremic HCV antibody carriers prior to the use of more sophisticated molecular typing techniques, and may be helpful in tracking transmissions routes.

Hepatitis C virus genotypes: An investigation of type‐specific differences in geographic origin and disease

The data suggest significant geographic clustering of type 4 disease in the Middle East area and poor response to interferon‐α was noted in patients with type 1 disease, which may have important clinical implications.

Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases: A multi‐institution analysis

SG‐1 HCV was found to predominate in Japan, and the HCV genotypes were found to be related to the stage of hepatitis C disease.

Clinical significance of hepatitis C antibodies in blood donors

It is concluded that HCV antibodies found coincidentally in Finnish donors seldom indicates severe liver disease.

HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile

Genotype 3a was correlated to IVDU or tattooing as parenteral risk factors for the acquisition of HCV infection, and genotype 2b to prior blood transfusion, and donors with genotypes 1a seemed to have less severe liver disease.

Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non‐A, non‐B hepatitis patients

To establish the value of the second‐generation recombinant immunoblot assay (RIBA‐2) and cDNA polymerase chain reaction (cDNA PCR) for confirmation of hepatitis C virus (HCV) infection, anti‐HCV

Markers of hepatitis C and B virus infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam.

Results indicate an extensive spread of HCV among Ho Chi Minh City donors and HCV of novel genotypes in vietnam.



Patterns of serological markers in transfusion‐transmitted hepatitis C virus infection using second‐generation HCV assays

It is concluded that combined application of anti‐HCV immunoblot techniques and cDNA‐PCR in consecutive samples is necessary for reliable diagnosis of either ongoing productive or resolving HCV infection.

Risk factors in hepatitis C virus‐infected blood donors

The prevalence of confirmed HCV infection among Amsterdam blood donors is calculated at 0.04 percent; parenteral exposure appears to be the major risk factor forHCV infection.

Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors.

The detection of anti-HCV in donors who have neither an elevation of alanine aminotransferase level nor presence of antibody to hepatitis B core antigen suggests that donor screening for anti- HCV will further reduce the risk of transfusion-associated hepatitis.

Analysis of genomic variability of hepatitis C virus.

Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.

The screening of blood donors for anti- HCV antibody should prevent about half the cases of transfusion-associated hepatitis, but the donors with infectious virus who are anti-HCV-negative may remain seronegative for prolonged periods.

Hepatitis C Viraemia in United Kingdom Blood Donors: A Multicentre Study

While first generation anti‐HCV screening assays generate a high proportion of false reactions when screening low prevalence populations, results of the RIBA‐2 confirmatory test correlate well with PCR findings and thus indirectly with both hepatitis C viraemia and infectivity.

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Assays of ten blood transfusions in the United States that resulted in chronic NANBH revealed that there was at least one positive blood donor in nine of these cases and that all ten recipients seroconverted during their illnesses.

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

It is concluded that hepatitis C virus is the predominant agent of transfusion-associated non-A, non-B hepatitis and that screening of donors for anti-HCV could prevent the majority of cases of the disease.